Drug Trial Radar · NCT05781152
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,270
Actual
Start
Jun 10, 2023
Primary completion
Jul 1, 2028
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- Connecticut Children's Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory University; Children's Hospital Medical Center, Cincinnati; University of North Carolina, Chapel Hill
- First posted
- Mar 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.
Conditions
- Crohn Disease
Interventions
Anti-TNF therapyDrug
Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete healing (CH)Time frame: 52 weeks from anti-TNF start
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Cedars-Sinai
Los Angeles, California
Rady Children's Hospital - San Diego and University of California, San Diego
San Diego, California
UCSF Benioff Children's Hospitals
San Francisco, California
Connecticut Children's Medical Center
Hartford, Connecticut
Emory University
Atlanta, Georgia
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana
The Johns Hopkins Children's Medical Center
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Goryeb Children's Hospital/Morristown Medical Center/Atlantic Children's Health
Morristown, New Jersey
Cohen Children's Medical Center of NY
Lake Success, New York
Columbia University Medical Center
New York, New York
Levine Children's
Charlotte, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
UH/Rainbow Babies and Children's Hospital
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Seattle Children's Hospital
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Stollery Children's Hospital
Edmonton, Alberta, Canada
Children's Hospital Western Ontario
London, Ontario, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Toronto SickKids Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.